Comprehensive Management of Hepatocellular Carcinoma: A Review of Current Surgical, Locoregional, and Systemic Therapies | ||||
| ERU Research Journal | ||||
| Articles in Press, Accepted Manuscript, Available Online from 19 August 2024 PDF (250.23 K) | ||||
| Document Type: Review articles | ||||
| DOI: 10.21608/erurj.2024.300146.1165 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Omnia Ahmed  1; Rehab H. Werida2; Safaa Askar3; Marwa A. El Mohamdy4; Gamal A. Omran5; Radwa Samir Hagag 6
| ||||
| 1Clinical pharmacy and pharmacy practice, Faculty of pharmacy, Egyptian Russian University, Cairo, Egypt | ||||
| 2Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt | ||||
| 3Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
| 4Clinical Pathology Department, Faculty of Medicine, Ain shams university, Cairo, Egypt. | ||||
| 5Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. | ||||
| 6Assistant Professor in department of Clinical pharmacy and pharmacy practice, Faculty of pharmacy, Egyptian Russian University, Cairo, Egypt | ||||
| Abstract | ||||
| The most frequent primary liver cancer is called hepatocellular carcinoma (HCC), which presents serious clinical difficulties because of its aggressiveness and frequently late-stage diagnosis. A significant health burden in Egypt is associated with hepatitis C virus (HCV) infection, which is highly prevalent. Liver resection and liver transplantation are two possibilities for curative treatment; each has advantages and disadvantages of its own. For tiny tumors, local ablative therapies including cryoablation, microwave ablation, and radiofrequency ablation (RFA) work well. Systemic therapies including sorafenib, lenvatinib, and immunotherapy are essential for advanced stages of HCC, while locoregional therapies, such as transarterial chemoembolization (TACE) and transarterial radioembolization (TARE), target intermediate-stage HCC. Novel approaches, like gene therapy and combination medicines, demonstrate the continuous progress in HCC treatment. In order to improve patient outcomes, effective therapy requires a multidisciplinary strategy that includes supportive and palliative care. Improving prognosis requires early discovery using diagnostic imaging and biomarkers, as well as screening programs. In order to maximize HCC management and patient care, it is crucial to comprehend the intricate interactions between staging systems, prognostic variables, and therapeutic modalities. | ||||
| Keywords | ||||
| Keywords: Hepatocellular carcinoma; Liver resection; Transarterial chemoembolization and Immunotherapy | ||||
|
Statistics Article View: 59 PDF Download: 78 |
||||
